✦ LIBER ✦

Phase I Clinical Trial Targeting CD20+ Non-Hodgkin'S Lymphoma (NHL) After Autologous Stem Cell Transplant With Anti-CD3 × Anti-CD20 Bispecific Antibody Armed T Cells

✍ Scribed by L.G. Lum; A. Thakur; V. Ratanatharathorn; Z. Al-Kadhimi; E. Paul; C. Skuba; P. Steel; L. Ayash; M. Abidi; J. Wedge; J.P. Uberti

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immune consolidation after stem cell tra

✍ L.G. Lum; P. Davol; G. Colvin; R. Rathore; M. Abedi; E. Palushock; A. Olson; T. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Targeting Myeloma Stem Cells with T Cell

✍ L.G. Lawrence; T. Archana; A. Muneer; A.-K. Zaid; R. Voravit; Z. Jeffrey; A. Loi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Phase II trial of 131I-B1 (anti-CD20) an

✍ O.W Press; F Appelbaum; P.J Martin; D.C Matthews; I.D Bernstein; J.F Eary; W.B N 📂 Article 📅 1995 🏛 The Lancet 🌐 English ⚖ 699 KB

Activated T cells from umbilical cord bl

✍ Archana Thakur; Carly Sorenson; Oxana Norkina; Dana Schalk; Voravit Ratanatharat 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 922 KB

Rituximab (anti-CD20 monoclonal antibody

✍ Tsai, D E; Moore, H C F; Hardy, C L; Porter, D L; Loh, E Y; Vaughn, D J; Luger, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 52 KB

Immunotherapy with FBTA05 (Bi20), a trif

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB